Company · NVS
Novartis
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
224
116 still marketed
Novel approvals
86
Approvals since 2021
85
Originals and new uses
Phase 3 trials
1,124
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Enzeevu approved Oct 22, 2026
- Cosentyx new use Oct 15, 2026
- Rhapsido new use Oct 6, 2026
- Pluvicto new use Jul 31, 2026
- Fabhalta new use Priority reviewJul 16, 2026
- Kisqali Femara CO-Pack (Copackaged) new use Priority reviewJul 1, 2026
- Kisqali new use Priority reviewJul 1, 2026
- Cosentyx new use Priority reviewApr 17, 2026
- Cosentyx new use Priority reviewApr 17, 2026
- Cosentyx new use Mar 12, 2026
Drugs in development (59)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- PelacarsenTQJ230Phase 37 trials
Novartis · Cardiovascular Disease and Lipoprotein(a), Atherosclerotic Cardiovascular Disease (ASCVD), Atherosclerotic Cardiovascular Disease
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- KLU156Phase 34 trials
Novartis · Uncomplicated Plasmodium Falciparum Malaria
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- 177Lu-PSMA-617Lutetium [177Lu] vipivotide tetraxetan, lutetium vipivotide tetraxetanPhase 33 trials
Novartis · Prostatic Neoplasms, Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)
- AbelacimabMAA868Phase 33 trials
Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke
- Lutetium[177Lu] Oxodotreotidedotatate, 177Lu-DOTA0-Tyr3-OctreotatePhase 33 trials
Sinotau Pharmaceutical Group · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- [68Ga]Ga-DOTA-TATEAAA501Phase 32 trials
Novartis · Extensive Stage Small Cell Lung Cancer, Neuroendocrine Neoplasms
- AAA817[225Ac]Ac-PSMA-617Phase 32 trials
Novartis · Prostate Cancer
- ARDTPhase 32 trials
Novartis · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- ARPI: EnzalutamideARPI abirateronePhase 32 trials
Novartis · Metastatic Castration Resistant Prostate Cancer (mCRPC), Prostate Cancer
- NaporafenibLXH254, ERAS-254Phase 32 trials
Novartis · Melanoma, Advanced or Metastatic NRAS-mutant Melanoma
- GME751Phase 31 trial
Novartis · Metastatic NSCLC
- QMF149Phase 31 trial
Novartis · Asthma
- QVM149Phase 31 trial
Novartis · Asthma
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
- KAE609CipargaminPhase 25 trials
Novartis · Uncomplicated Plasmodium Falciparum Malaria, Severe Malaria
- luxdegalutamideJSB462, ARV-766Phase 24 trials
Novartis · Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic
- MAS825ArumakimigPhase 24 trials
Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- DDY391Phase 23 trials
Novartis · Moderate to Severe Psoriatic Arthritis, Sjögren's Disease
- GIA632Phase 23 trials
Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07225504 · 1,275 participants (planned) · Start Nov 11, 2025 · Primary completion Dec 3, 2030
Drug: Remibrutinib (blinded); Placebo and 1 more · For: Secondary Progressive Multiple Sclerosis (SPMS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 296 sites in all
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07326709 · 770 participants (planned) · Start Mar 24, 2026 · Primary completion Apr 2, 2030
Drug: Votoplam (blinded); Placebo · For: Huntington Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 117 sites in all
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07665437 · 710 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 15, 2031
Drug: Remibrutinib · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fort Smith, Arkansas; North Little Rock, Arkansas · 61 sites in all
- Remibrutinib Open Label Roll-over Post-trial Access ProtocolPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07456891 · 650 participants (planned) · Start Apr 16, 2026 · Primary completion Jan 30, 2033
Drug: Remibrutinib · For: Indication of the Parent Protocol
Sites: Sofia, Bulgaria; Varna, Bulgaria; Fredericton, Canada · 46 sites in all
- A 52-week Study of Remibrutinib in IgE-mediated Food AllergyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07768371 · 576 participants (planned) · Start Aug 27, 2026 · Primary completion Mar 30, 2029
Drug: Remibrutinib; Placebo · For: IgE-Mediated Food Allergy; Peanut Allergy; Cow Milk Allergy and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 22 sites in all
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07621809 · 570 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 15, 2029
Drug: VAY736; Placebo · For: Sjögren´s Disease
Sites: Peoria, Arizona; Searcy, Arkansas; Van Nuys, California · 72 sites in all
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06133972 · 550 participants (planned) · Start May 21, 2024 · Primary completion Apr 3, 2034
Drug: Placebo; Ianalumab · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Burbank, California; La Palma, California · 167 sites in all
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04557462 · 540 participants (planned) · Start Sep 20, 2021 · Primary completion Dec 4, 2030
Drug: LNP023 · For: Primary IgA Nephropathy
Sites: Glendale, Arizona; San Diego, California; San Dimas, California · 161 sites in all
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07357727 · 460 participants (planned) · Start May 27, 2026 · Primary completion May 17, 2028
Drug: Pelabresib; Ruxolitinib and 1 more · For: Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Sites: Denver, Colorado; New Haven, Connecticut; Fort Myers, Florida · 174 sites in all
Marketed drugs (116)
Newest FDA action first.
- Estradiol Estradiol · 1996
- Piqray Alpelisib · 2019
- Jubbonti Denosumab-Bbdz · 2024
- Enzeevu Aflibercept-Abzv · 2026
- Cosentyx Secukinumab · 2015
- Cosentyx Secukinumab · 2023
- Rhapsido Remibrutinib · 2025
- Scemblix Asciminib Hydrochloride · 2021
- Zortress Everolimus · 2010
- Leqvio Inclisiran Sodium · 2021
- Durezol Difluprednate · 2008
- Pluvicto Lutetium Lu-177 Vipivotide Tetraxetan · 2022
- Myfortic Mycophenolate Sodium · 2004
- Tyruko Natalizumab-Sztn · 2023
- Fabhalta Iptacopan Hydrochloride · 2023
- Tegretol Carbamazepine · 1987
- Tegretol-Xr Carbamazepine · 1996
- Tegretol Carbamazepine · 1968
- Gleevec Imatinib Mesylate · 2003
- Kisqali Femara CO-Pack (Copackaged) Letrozole, Ribociclib Succinate · 2017
- Kisqali Ribociclib Succinate · 2017
- Mayzent Siponimod · 2019
- Afinitor Disperz Everolimus · 2012
- Afinitor Everolimus · 2009
- Sandimmune Cyclosporine · 1983
- Ziextenzo Pegfilgrastim-Bmez · 2019
- Mekinist Trametinib Dimethyl Sulfoxide · 2013
- Kesimpta Ofatumumab · 2009
- Tafinlar Dabrafenib Mesylate · 2013
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · 2023
- Tafinlar Dabrafenib Mesylate · 2023
- Sandimmune Cyclosporine · 1990
- Sandimmune Cyclosporine · 1983
- Reclast Zoledronic Acid · 2007
- Pemetrexed Disodium Pemetrexed Disodium · 2022
- Qoliana Brimonidine Tartrate · 2006
- Vanrafia Atrasentan Hydrochloride · 2025
- Hyrimoz Adalimumab-Adaz · 2018
- Travatan Z Travoprost · 2006
- Focalin Xr Dexmethylphenidate Hydrochloride · 2005
- Trileptal Oxcarbazepine · 2000
- Ritalin La Methylphenidate Hydrochloride · 2002
- Trileptal Oxcarbazepine · 2001
- Gilenya Fingolimod Hydrochloride · 2010
- Zarxio Filgrastim-Sndz · 2015
- Vijoice Alpelisib · 2022
- Vijoice Alpelisib · 2024
- Diovan Valsartan · 2001
- Omnitrope Somatropin · 2006
- Promacta Kit Eltrombopag Olamine · 2015
- Promacta Eltrombopag Olamine · 2008
- Tobradex Dexamethasone, Tobramycin · 1988
- Locametz Gallium Ga-68 Gozetotide · 2022
- Arranon Nelarabine · 2005
- Ritalin Methylphenidate Hydrochloride · 1955
- Cyclophosphamide Cyclophosphamide · 2023
- Omnipred Prednisolone Acetate · 1973
- Femara Letrozole · 1997
- Infuvite Pediatric (Pharmacy Bulk Package) Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol Acetate, Vitamin A, Vitamin K · 2001
- Infuvite Adult Alpha-Tocopherol Acetate, Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine Hydrochloride, Riboflavin 5'-Phosphate Sodium, Thiamine Hydrochloride, Vitamin A Palmitate, Vitamin K · 2000
- Ilaris Canakinumab · 2009
- Tasigna Nilotinib Hydrochloride · 2007
- Beovu Brolucizumab-Dbll · 2019
- Sandostatin Lar Octreotide Acetate · 1998
- Sandostatin Octreotide Acetate · 1988
- Adakveo Crizanlizumab-Tmca · 2019
- Timolol Maleate Timolol Maleate · 1998
- Cimerli Ranibizumab-Eqrn · 2022
- Exelon Rivastigmine · 2007
- Entresto Sprinkle Sacubitril, Valsartan · 2024
- Entresto Sacubitril, Valsartan · 2015
- Tabrecta Capmatinib Hydrochloride · 2020
- Votrient Pazopanib Hydrochloride · 2009
- Lescol Xl Fluvastatin Sodium · 2000
- Anectine Succinylcholine Chloride · 1952
- Netspot Gallium Dotatate Ga-68 · 2016
- Focalin Dexmethylphenidate Hydrochloride · 2001
- Neoral Cyclosporine · 1997
- Neoral Cyclosporine · 1997
- Neoral Cyclosporine · 1997
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.